NYSEArca - Delayed Quote USD

Capital Group International Focus Equity ETF (CGXU)

26.87 +0.19 (+0.71%)
At close: October 11 at 4:00 PM EDT
Loading Chart for CGXU
DELL
  • Previous Close 26.68
  • Open 26.68
  • Bid 26.02 x 900
  • Ask 27.59 x 1300
  • Day's Range 26.67 - 26.91
  • 52 Week Range 20.80 - 27.52
  • Volume 295,908
  • Avg. Volume 409,767
  • Net Assets 3.1B
  • NAV 26.75
  • PE Ratio (TTM) 20.00
  • Yield 0.93%
  • YTD Daily Total Return 13.24%
  • Beta (5Y Monthly) 0.00
  • Expense Ratio (net) 0.54%

The fund invests primarily in common stocks of companies domiciled outside the United States, including companies domiciled in emerging markets (but in no fewer than three countries), that the investment adviser believes have the potential for growth. It normally invests at least 80% of its assets in equity securities. The fund is non-diversified.

Capital Group

Fund Family

Foreign Large Growth

Fund Category

3.1B

Net Assets

2022-02-22

Inception Date

Performance Overview: CGXU

View More

Trailing returns as of 10/11/2024. Category is Foreign Large Growth.

YTD Return

CGXU
13.24%
Category
12.94%
 

1-Year Return

CGXU
23.08%
Category
26.69%
 

3-Year Return

CGXU
0.00%
Category
0.19%
 

People Also Watch

Holdings: CGXU

View More

Top 9 Holdings (29.59% of Total Assets)

SymbolCompany% Assets
NOVO-B.CO
Novo Nordisk A/S 4.52%
4568.T
Daiichi Sankyo Company, Limited 4.18%
RELIANCE.NS
Reliance Industries Limited 3.50%
6098.T
Recruit Holdings Co., Ltd. 3.45%
MELI
MercadoLibre, Inc. 2.90%
NU
Nu Holdings Ltd. 2.87%
2330.TW
Taiwan Semiconductor Manufacturing Company Limited 2.74%
AIR.PA
Airbus SE 2.74%
FM.TO
First Quantum Minerals Ltd. 2.69%

Sector Weightings

SectorCGXU
Technology   15.97%
Industrials   15.30%
Healthcare   13.10%
Energy   6.25%
Utilities   0.60%
Real Estate   0.56%

Related ETF News

View More

Research Reports: CGXU

View More
  • Pfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target
     
  • What does Argus have to say about BB?

    BLACKBERRY LTD has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
     
  • Johnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars

    Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

    Rating
    Price Target
     
  • New products and M&A drive 2024 growth

    Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.

    Rating
    Price Target
     

Related Tickers